A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other OAD
Phase of Trial: Phase III
Latest Information Update: 17 Apr 2019
Price : $35 *
At a glance
- Drugs Insulin degludec/liraglutide (Primary) ; Insulin degludec; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms DUAL™ II China
- Sponsors Novo Nordisk
- 15 Apr 2019 Status changed from active, no longer recruiting to completed.
- 09 Jan 2019 Planned primary completion date changed from 10 Dec 2018 to 8 Mar 2019.
- 24 Oct 2018 Planned End Date changed from 13 May 2019 to 8 Apr 2019.